Literature DB >> 21872549

Mesenteric myofibroblastic tumor: NSAID therapy after incomplete resection.

B Diop1, I Konate, S Ka, I Sall, D Fall, M Dieng, Y Wone.   

Abstract

Myofibroblastic tumors are inflammatory tumors that arise in viscera and soft tissue; their etiopathology is poorly understood. They are capable of infiltration of adjacent organs, local recurrence after surgical resection, and even of distant metastasis. These characteristics result in persistent debate as to the nature of these lesions - whether they are inflammatory or neoplastic, benign or malignant lesions? Diagnosis is almost always made based on histopathological findings. Traditional management is complete surgical excision, but this may be difficult or impossible when the lesion develops in proximity to vital structures. We report the case of a 59-year-old man who was treated in our institution for mesenteric myofibroblastic tumor. Complete resection was not possible due to local infiltration of the mesentery. Recurrence was noted 3 months after surgery; treatment with steroidal and then non-steroidal anti-inflammatory medications (NSAIDs) resulted in clinical and radiologic regression of the tumor.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872549     DOI: 10.1016/j.jviscsurg.2011.06.005

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  7 in total

Review 1.  Review of the progress toward achieving heat confinement-the holy grail of photothermal therapy.

Authors:  Wangzhong Sheng; Sha He; William J Seare; Adah Almutairi
Journal:  J Biomed Opt       Date:  2017-08-01       Impact factor: 3.170

Review 2.  Mesenteric inflammatory pseudotumor: a case report and comprehensive literature review.

Authors:  Yusuf Yagmur; Sami Akbulut; Serdar Gumus
Journal:  J Gastrointest Cancer       Date:  2014-12

3.  Inflammatory myofibroblastic tumor successfully treated with chemotherapy and nonsteroidals: a case report.

Authors:  Yun-Lu Tao; Zhen-Jun Wang; Jia-Gang Han; Ping Wei
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

4.  MRI characterization of inflammatory myofibroblastic tumors in the maxillofacial region.

Authors:  Hui Li; De Ling Wang; Xue Wen Liu; Zhi Jun Geng; Chuan Miao Xie
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

5.  Analysis of clinical features and outcomes for inflammatory myofibroblastic tumors in China: 11 years of experience at a single center.

Authors:  Zuopeng Wang; Xiaolong Zhao; Kai Li; Wei Yao; Kuiran Dong; Xianmin Xiao; Shan Zheng
Journal:  Pediatr Surg Int       Date:  2015-11-21       Impact factor: 1.827

6.  Complete resection of a huge hypervascular inflammatory myofibroblastic tumor in right hemithorax after embolization.

Authors:  Kyu-Nam Kim; Dong-Won Kim
Journal:  World J Pediatr       Date:  2016-06-10       Impact factor: 2.764

7.  Remission of ALK-negative primary pulmonary inflammatory myofibroblastic tumor on treatment with clarithromycin: A case report and review of the literature.

Authors:  Hidehiro Watanabe; Tomonori Uruma; Gen Tazaki; Takuma Tajiri; Ryota Kikuchi; Masayuki Itoh; Kazutetsu Aoshiba; Hiroyuki Nakamura
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.